Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.46 |
| ▸ | TEC | P42680 | 3/20 | 0.45 |
| ▸ | BMX | P51813 | 3/20 | 0.45 |
| ▸ | TXK | P42681 | 2/20 | 0.45 |
| ▸ | LYN | P07948 | 2/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.45 |
| ▸ | LATS1 | O95835 | 1/20 | 0.45 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | FYN | P06241 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24458365 | 0.94 | BTK (0.49) | BTKEGFRITKFGFR2TEC | |
| SCHEMBL31523833 | 0.94 | BTK (0.49) | BTKEGFRITKFGFR2TEC | |
| SCHEMBL24458360 | 0.93 | ITK (0.54) | BTKITKFGFR1FGFR4FGFR2 | |
| SCHEMBL24458392 | 0.93 | BTK (0.51) | BTKEGFRTECBMXTXK | |
| SCHEMBL31523719 | 0.93 | BTK (0.48) | BTKEGFRITKFGFR1FGFR4 | |
| SCHEMBL24458394 | 0.93 | BTK (0.48) | BTKEGFRITKFGFR1FGFR4 | |
| SCHEMBL31523790 | 0.91 | ITK (0.46) | BTKEGFRITKFGFR1FGFR4 | |
| SCHEMBL24459014 | 0.91 | ITK (0.46) | BTKEGFRITKFGFR1FGFR4 | |
| SCHEMBL24458712 | 0.91 | BTK (0.49) | BTKEGFRITKFGFR1FGFR4 | |
| SCHEMBL31523768 | 0.91 | BTK (0.49) | BTKEGFRITKFGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| WO-2022109551-A1 | SRC INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154154-A1 | SRC INHIBITORS AND USES THEREOF | SRC, LCK, FYN | BTK 7/4885EGFR 51/4885ITK 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.